Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment. Follow him on Twitter: @montypal
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)
Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)
Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
